Clinical Trial

Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage

Study acronym: CASH
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-20.
Trial Details
NCT Number NCT07144956
Lead Sponsor Centre Hospitalier St Anne
Conditions Aneurysmal Subarachnoid Hemorrhage
Enrollment 630 participants
Start Date 2025-12-15
Primary Completion 2029-12-14 (estimated)
Study Completion 2029-12-14 (estimated)
Updated on ClinicalTrials.gov 2025-09-10